BACKGROUND: The response to immunotherapy can be impaired by several factors including external intervention such as drug interactions with immune system. We aimed to examine the immunomodulatory action of opioids, since immune cells express opioid receptors able to negatively influence their activities. METHODS: This observational, multicenter, retrospective study, recruited patients with different metastatic solid tumors, who have received immunotherapy between September 2014 and September 2019. Immunotherapy was administered according to the standard schedule approved for each primary tumor and line of treatment. The concomitant intake of antibiotics, antifungals, corticosteroids and opioids were evaluated in all included patients. The relationship between tumor response to immunotherapy and the oncological outcomes were evaluated. A multivariate Cox-proportional hazard model was used to identify independent prognostic factors for survival. RESULTS: One hundred ninety-three patients were recruited. Overall, progression-free survival (PFS) and overall survival (OS) were significantly shorter in those patients taking opioids than in those who didn't (median PFS, 3 months vs. 19 months, HR 1.70, 95% CI 1.37-2.09, p < 0.0001; median OS, 4 months vs. 35 months, HR 1.60, 95% CI 1.26-2.02, p < 0.0001). In addition, PFS and OS were significantly impaired in those patients taking corticosteroids, antibiotics or antifungals, in those patients with an ECOG PS ≥ 1 and in patients with a high tumor burden. Using the multivariate analyses, opioids and ECOG PS were independent prognostic factors for PFS, whereas only ECOG PS resulted to be an independent prognostic factor for OS, with trend toward significance for opioids as well as tumor burden. DISCUSSION: Our study suggests that the concomitant administration of drugs as well as some clinical features could negatively predict the outcomes of cancer patients receiving immunotherapy. In particular, opioids use during immunotherapy is associated with early progression, potentially representing a predictive factor for PFS and negatively influencing OS as well. CONCLUSIONS: A possible negative drug interaction able to impair the immune response to anti-PD-1/PD-L1 agents has been highlighted. Our findings suggest the need to further explore the impact of opioids on immune system modulation and their role in restoring the response to immunotherapy treatment, thereby improving patients' outcomes.
BACKGROUND: The response to immunotherapy can be impaired by several factors including external intervention such as drug interactions with immune system. We aimed to examine the immunomodulatory action of opioids, since immune cells express opioid receptors able to negatively influence their activities. METHODS: This observational, multicenter, retrospective study, recruited patients with different metastatic solid tumors, who have received immunotherapy between September 2014 and September 2019. Immunotherapy was administered according to the standard schedule approved for each primary tumor and line of treatment. The concomitant intake of antibiotics, antifungals, corticosteroids and opioids were evaluated in all included patients. The relationship between tumor response to immunotherapy and the oncological outcomes were evaluated. A multivariate Cox-proportional hazard model was used to identify independent prognostic factors for survival. RESULTS: One hundred ninety-three patients were recruited. Overall, progression-free survival (PFS) and overall survival (OS) were significantly shorter in those patients taking opioids than in those who didn't (median PFS, 3 months vs. 19 months, HR 1.70, 95% CI 1.37-2.09, p < 0.0001; median OS, 4 months vs. 35 months, HR 1.60, 95% CI 1.26-2.02, p < 0.0001). In addition, PFS and OS were significantly impaired in those patients taking corticosteroids, antibiotics or antifungals, in those patients with an ECOG PS ≥ 1 and in patients with a high tumor burden. Using the multivariate analyses, opioids and ECOG PS were independent prognostic factors for PFS, whereas only ECOG PS resulted to be an independent prognostic factor for OS, with trend toward significance for opioids as well as tumor burden. DISCUSSION: Our study suggests that the concomitant administration of drugs as well as some clinical features could negatively predict the outcomes of cancer patients receiving immunotherapy. In particular, opioids use during immunotherapy is associated with early progression, potentially representing a predictive factor for PFS and negatively influencing OS as well. CONCLUSIONS: A possible negative drug interaction able to impair the immune response to anti-PD-1/PD-L1 agents has been highlighted. Our findings suggest the need to further explore the impact of opioids on immune system modulation and their role in restoring the response to immunotherapy treatment, thereby improving patients' outcomes.
Authors: Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz Journal: N Engl J Med Date: 2020-12-03 Impact factor: 91.245
Authors: Roy S Herbst; Edward B Garon; Dong-Wan Kim; Byoung Chul Cho; Jose L Perez-Gracia; Ji-Youn Han; Catherine Dubos Arvis; Margarita Majem; Martin D Forster; Isabelle Monnet; Silvia Novello; Zsuzsanna Szalai; Matthew A Gubens; Wu-Chou Su; Giovanni Luca Ceresoli; Ayman Samkari; Erin H Jensen; Gregory M Lubiniecki; Paul Baas Journal: J Clin Oncol Date: 2020-02-20 Impact factor: 44.544
Authors: Siwen Hu-Lieskovan; Aaron Lisberg; Jesse M Zaretsky; Tristan R Grogan; Hira Rizvi; Daniel K Wells; James Carroll; Amy Cummings; John Madrigal; Benjamin Jones; Jacklin Gukasyan; I Peter Shintaku; Dennis Slamon; Steven Dubinett; Jonathan W Goldman; David Elashoff; Matthew D Hellmann; Antoni Ribas; Edward B Garon Journal: Clin Cancer Res Date: 2019-05-21 Impact factor: 12.531
Authors: Thomas Powles; Elizabeth R Plimack; Denis Soulières; Tom Waddell; Viktor Stus; Rustem Gafanov; Dmitry Nosov; Frédéric Pouliot; Bohuslav Melichar; Ihor Vynnychenko; Sergio J Azevedo; Delphine Borchiellini; Raymond S McDermott; Jens Bedke; Satoshi Tamada; Lina Yin; Mei Chen; L Rhoda Molife; Michael B Atkins; Brian I Rini Journal: Lancet Oncol Date: 2020-10-23 Impact factor: 41.316
Authors: Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway Journal: Science Date: 2015-09-10 Impact factor: 47.728
Authors: Robert J Motzer; Bernard Escudier; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Elizabeth R Plimack; Giuseppe Procopio; David F McDermott; Daniel Castellano; Toni K Choueiri; Frede Donskov; Howard Gurney; Stéphane Oudard; Martin Richardet; Katriina Peltola; Ajjai S Alva; Michael Carducci; John Wagstaff; Christine Chevreau; Satoshi Fukasawa; Yoshihiko Tomita; Thomas C Gauler; Christian K Kollmannsberger; Fabio A Schutz; James Larkin; David Cella; M Brent McHenry; Shruti Shally Saggi; Nizar M Tannir Journal: Cancer Date: 2020-07-16 Impact factor: 6.860
Authors: Jake S O'Donnell; Georgina V Long; Richard A Scolyer; Michele W L Teng; Mark J Smyth Journal: Cancer Treat Rev Date: 2016-11-27 Impact factor: 12.111
Authors: Timothy O'Sullivan; Robert Saddawi-Konefka; William Vermi; Catherine M Koebel; Cora Arthur; J Michael White; Ravi Uppaluri; Daniel M Andrews; Shin Foong Ngiow; Michele W L Teng; Mark J Smyth; Robert D Schreiber; Jack D Bui Journal: J Exp Med Date: 2012-08-27 Impact factor: 14.307
Authors: Jonathan B Yuval; Jasme Lee; Fan Wu; Hannah M Thompson; Floris S Verheij; Hersh V Gupta; Takeshi Irie; Joseph R Scarpa; Patrick J McCormick; J Joshua Smith; Jinru Shia; Martin R Weiser; Francisco Sánchez-Vega; Kay See Tan; Gregory W Fischer; Julio Garcia-Aguilar; Joshua S Mincer Journal: Br J Anaesth Date: 2022-06-17 Impact factor: 11.719